Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1996-10-3
|
| pubmed:abstractText |
Adrenal medullary chromaffin cells produce high levels of endogenous opioid peptides. Recent data suggest that transplantation injected locally into the spinal subarachnoid space reduced intractable malignant pain. In order to determine the feasibility, the efficacy and the risks of using adrenal medullary tissue for control of irreducible pain, we have developed a transplantation protocol on cancer pain patients selected when they required chronic intrathecal injection of morphine and progressively increasing doses to maintain the level of analgesic effects. At the present time, our clinical trial involves 8 patients. We report here our initial results (mean follow-up: 5 months). The various data collected before and after the intrathecal administration of chromaffin cells included: 1) Pain evaluation over time, with concomitant narcotic intake, 2) CSF sampling through an implanted access port to determine the following biological parameters: biochemical assay for opioid peptides, cell count and phenotyping of lymphocytes, 3) peripheral blood samples for lymphocyte typing. The results confirm the efficacy of adrenal medullary transplantation into spinal CSF for controlling irreducible cancer pain. Complementary intrathecal and oral morphine were totally stopped in 2 cases and stabilized in 5 others. It seems essential to have an important volume of grafted tissue to achieve analgesia with high levels of metenkephalin in CSF. A progressive decrease in metenkephalin release was observed from 2 to 4 months after the transplantation. Two patients with a long-term follow-up (8 and 12 months) needed another intrathecal chromaffin cell graft.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0065-1419
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
64
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
97-100
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8748593-Adrenal Medulla,
pubmed-meshheading:8748593-Adult,
pubmed-meshheading:8748593-Aged,
pubmed-meshheading:8748593-Aged, 80 and over,
pubmed-meshheading:8748593-Chromaffin System,
pubmed-meshheading:8748593-Enkephalin, Methionine,
pubmed-meshheading:8748593-Feasibility Studies,
pubmed-meshheading:8748593-Female,
pubmed-meshheading:8748593-Humans,
pubmed-meshheading:8748593-Male,
pubmed-meshheading:8748593-Middle Aged,
pubmed-meshheading:8748593-Neoplasms,
pubmed-meshheading:8748593-Nociceptors,
pubmed-meshheading:8748593-Opioid Peptides,
pubmed-meshheading:8748593-Pain, Intractable,
pubmed-meshheading:8748593-Pain Measurement,
pubmed-meshheading:8748593-Subarachnoid Space,
pubmed-meshheading:8748593-Transplantation, Homologous,
pubmed-meshheading:8748593-Treatment Outcome
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Transplantation of human chromaffin cells for control of intractable cancer pain.
|
| pubmed:affiliation |
Department of Neurosurgery, Faculty of Medicine, University Paul Sabatier, Toulouse, France.
|
| pubmed:publicationType |
Journal Article
|